HOPA Now is the official podcast of the Hematology/Oncology/Pharmacy Association, an organization dedicated to supporting pharmacy practitioners and promoting the advancement of Hematology/Oncology/Pharmacy to optimize the care of individuals impacted by cancer.

 

These educational podcasts are part of our BCOP Preparatory and Recertification Course, which is designed to prepare oncology pharmacists preparing to sit for the BCOP Certification Exam, as well as meet the BPS requirement to complete a BCOP Preparatory/Recertification Review Course.

 

In this episode of HOPA Now, Dr. Shrina Patel offers an overview of the incessant ovulation theory, biopsy options for diagnosis and treatment, and the progression and timing of HPV to ovarian cancer over time. She also gives an overview of endometrial cancer based on epidemiology, histology, and prognosis, and explains the pathways of serous carcinoma and clear cell carcinoma in the treatment of endometrial cancer.

 

In this episode, you will learn:

 

Gynecologic Malignancies Fundamentals

• Defining the incessant ovulation theory as a potential cause of sporadic ovarian cancer
• Understanding how potential mutagenic lesions in DNA are normally encountered and common risk factors of ovarian cancer
• Biopsy options for diagnosis and fine needle aspiration warnings in treatment of ovarian cancer
• The progression and timing of HPV associated lesions to ovarian cancer
• Treatment of and demographics surrounding HPV
• An overview of endometrial cancer classifications based on epidemiology, histology, and prognosis
• The pathways of serous carcinoma and clear cell carcinoma in the treatment of endometrial cancer

 

Mentioned in This Episode:

HOPA

 

Quotes:

 

“The etiology of ovarian cancer is complex and incompletely understood.” — Dr. Shrina Patel

 

“The progression and timing of HPV associated lesions to ovarian cancer typically happens over ten to twenty years.” — Dr. Shrina Patel

 

“Type 2 cancers are considered high grade by definition and primarily include serous carcinoma and clear cell carcinoma.” — Dr. Shrina Patel